Published on: 20 December 2025

Unlocking Cardiovascular Benefits Beyond Weight Loss

Cardiovascular disease remains the leading cause of morbidity and mortality worldwide, particularly among individuals with overweight or obesity. This risk intensifies in patients with established atherosclerotic cardiovascular disease (ASCVD), even in the absence of diabetes. Recent advances in pharmacotherapy have introduced semaglutide and tirzepatide as effective agents for chronic weight management. However, their comparative impact on major adverse cardiovascular events (MACE) in real-world clinical settings has remained uncertain—until now.

A comprehensive real-world study analyzed the cardiovascular outcomes of semaglutide and tirzepatide in a large, insured U.S. population of adults aged 45 and older with overweight or obesity and established ASCVD but no diabetes. The study leveraged robust claims data to investigate whether these medications influence cardiovascular risk beyond their weight-reduction properties.

Semaglutide Demonstrates Superior Cardiovascular Risk Reduction

This retrospective cohort study utilized rigorous propensity score matching to ensure balanced patient characteristics. Over 10,000 patients were included in each treatment group, followed for an average of approximately eight months.

Semaglutide showed a compelling association with reduced cardiovascular risk compared to tirzepatide. Specifically, it lowered the risk of revised 3-point MACE—which includes myocardial infarction, stroke, and all-cause mortality—by 29%. Similarly, the risk of revised 5-point MACE, adding coronary revascularization and heart failure hospitalization, decreased by 22%. These benefits manifested early, with noticeable divergence in event rates as soon as two to three months after treatment initiation.

Importantly, secondary analyses focusing on patients who maintained treatment without interruption revealed even more pronounced reductions. Semaglutide decreased the risk of revised 3-point MACE by 57% and revised 5-point MACE by 43%. Furthermore, it significantly lowered the risk of myocardial infarction and hospitalization for heart failure. These findings underscore semaglutide’s robust cardiovascular protection in patients with overweight or obesity and ASCVD without diabetes.

Mechanistic Insights: Beyond Weight Loss

Contrary to expectations, the cardiovascular benefits observed with semaglutide appeared largely independent of weight loss. Exploratory data revealed that patients treated with tirzepatide experienced greater average weight reductions over 12 months. Yet, cardiovascular event rates favored semaglutide, suggesting mechanisms beyond simple adiposity reduction.

Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), exerts direct cardiovascular effects through multiple pathways. These include anti-inflammatory actions, endothelial function improvement, and modulation of cardiac electrophysiology. Such pleiotropic effects likely contribute to its early and sustained cardioprotective profile. In contrast, tirzepatide’s dual agonism of glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors has not demonstrated a similar cardiovascular advantage in patients without diabetes.

This molecule-specific benefit highlights the importance of understanding pharmacodynamics when selecting weight management therapies for cardiovascular risk reduction.

Clinical Implications for Healthcare Professionals

For healthcare professionals managing overweight or obese patients with ASCVD, this study offers pivotal evidence to guide therapeutic decisions. Semaglutide’s demonstrated superiority in reducing major cardiovascular events informs risk mitigation strategies beyond glycemic control or weight loss alone.

While tirzepatide remains an effective agent for glycemic management and weight reduction, its cardiovascular benefits in non-diabetic populations require further confirmation. Clinicians should weigh these findings when prescribing glucagon-like peptide-1 receptor agonists or dual agonists, particularly for patients at heightened cardiovascular risk.

Moreover, the early onset of semaglutide’s cardiovascular protection emphasizes the importance of timely initiation and adherence to therapy. Ensuring patients reach and maintain therapeutic doses may optimize outcomes.

Strengths, Limitations, and Future Directions

This study’s strengths include its large, nationally representative cohort and robust methodology minimizing confounding factors. The use of real-world data complements clinical trial evidence, reflecting everyday clinical practice.

Nonetheless, inherent limitations of retrospective claims analyses exist. Potential coding inaccuracies, unmeasured confounders such as lifestyle factors, and relatively short follow-up periods temper the findings. Additionally, the exclusion of patients with diabetes limits the applicability of results to that population segment.

Looking ahead, randomized controlled trials comparing semaglutide and tirzepatide in cardiovascular outcomes among non-diabetic patients will clarify causality and mechanisms. Extended follow-up studies will elucidate the durability of these benefits.

Conclusion: Semaglutide Emerges as a Cardiovascular Game-Changer in Weight Management

In summary, semaglutide offers significant and early reductions in major adverse cardiovascular events compared to tirzepatide among patients with overweight or obesity and established ASCVD without diabetes. These advantages appear independent of weight loss, underscoring a molecule-specific cardioprotective effect.

For healthcare professionals dedicated to optimizing weight management and cardiovascular health, semaglutide stands out as a powerful therapeutic option. Incorporating these insights into clinical practice can enhance patient outcomes and reduce the burden of cardiovascular disease in this high-risk population.

Source: DOI: 10.1111/dom.70436

LEARN MORE ABOUT THE MUSLIM WEIGHT MANAGEMENT